版本
5.0
创建日期
2005-11-16 15:48:42 UTC
更新日期
2021-09-14 15:40:00 UTC
登录号
HMDB0000038
地位
quantified
二级访问
HMDB00038

名称
Dihydrobiopterin
描述
Dihydrobiopterin, also known as BH2, 7,8-dihydrobiopterin, L-erythro-7,8-dihydrobiopterin, quinonoid dihydrobiopterin or q-BH2, belongs to the class of organic compounds known as biopterins and derivatives. These are coenzymes containing a 2-amino-pteridine-4-one derivative. Dihydrobiopterin is also classified as a pteridine. Pteridines are aromatic compounds composed of fused pyrimidine and pyrazine rings. Dihydrobiopterin is produced during the synthesis of neurotransmitters L-DOPA, dopamine, norepinephrine and epinephrine. It is restored to the required cofactor tetrahydrobiopterin via the NADPH-dependant reduction of dihydrobiopterin reductase. Dihydrobiopterin can also be converted to tetrahydrobiopterin by nitric oxide synthase (NOS) which is catalyzed by the flavoprotein "diaphorase" activity of NOS. This activity is located on the reductase (C-terminal) domain of NOS, whereas the high affinity tetrahydrobiopterin site involved in NOS activation is located on the oxygenase (N-terminal) domain (PMID: 8626754). Sepiapterin reductase (SPR) is another enzyme that plays a role in the production of dihydrobiopterin. SPR catalyzes the reduction of sepiapterin to dihydrobiopterin (BH2), the precursor for tetrahydrobiopterin (BH4). BH4 is a cofactor critical for nitric oxide biosynthesis and alkylglycerol and aromatic amino acid metabolism (PMID: 25550200). Dihydrobiopterin is known to be synthesized in several parts of the body, including the pineal gland. Dihydrobiopterin exists in all eukaryotes, ranging from yeast to humans. In humans, dihydrobiopterin is involved in several metabolic disorders including dihydropteridine reductase (DHPR) deficiency. DHPR deficiency is a severe form of hyperphenylalaninemia (HPA) due to impaired regeneration of tetrahydrobiopterin (BH4) leading to decreased levels of neurotransmitters (dopamine, serotonin) and folate in cerebrospinal fluid, and causing neurological symptoms such as psychomotor delay, hypotonia, seizures, abnormal movements, hypersalivation, and swallowing difficulties. Dihydrobiopterin is also associated with another metabolic disorder known as sepiapterin reductase deficiency (SRD). Sepiapterin reductase catalyzes the (NADP-dependent) reduction of carbonyl derivatives, including pteridines, and plays an important role in tetrahydrobiopterin biosynthesis. Low dihydrofolate reductase activity in the brain leads to the accumulation of dihydrobiopterin, which in turn, inhibits tyrosine and tryptophan hydroxylases. This uncouples neuronal nitric oxide synthase, leading to neurotransmitter deficiencies and neuronal cell death. SRD is characterized by low cerebrospinal fluid neurotransmitter levels and the presence of elevated cerebrospinal fluid dihydrobiopterin. SRD is characterized by motor delay, axial hypotonia, language delay, diurnal fluctuation of symptoms, dystonia, weakness, oculogyric crises, dysarthria, parkinsonian signs and hyperreflexia.
同义词
1:7,8-DIHYDROBIOPTERIN

2:L-Erythro-Q-dihydrobiopterin

3:Q-BH2

4:Quinonoid dihydrobiopterin

5:L-Erythro-7,8-dihydrobiopterin

6:L-Erythro-dihydrobiopterin

7:7,8-Dihydro-L-biopterin

8:BH2

9:Dihydrobiopterin

化学式
C9H13N5O3
平均分子量
239.2312
等位分子量
239.101839307
化学名称
2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-1,4,7,8-tetrahydropteridin-4-one
传统名称
dihydrobiopterin
CAS 登记号
6779-87-9
代谢物结构字符串
C[C@H](O)[C@H](O)C1=NC2=C(NC1)NC(N)=NC2=O
inchi标识符
InChI=1S/C9H13N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3,6,15-16H,2H2,1H3,(H4,10,11,13,14,17)/t3-,6-/m0/s1
印记键
FEMXZDUTFRTWPE-DZSWIPIPSA-N
分类学
description: belongs to the class of organic compounds known as biopterins and derivatives. These are coenzymes containing a 2-amino-pteridine-4-one derivative. They are mainly synthesized in several parts of the body, including the pineal gland.

description:Biopterins and derivatives

kingdom:Organic compounds

super_class:Organoheterocyclic compounds

class:Pteridines and derivatives

sub_class:Pterins and derivatives

molecular_framework:Aromatic heteropolycyclic compounds

1:1,2-diols

2:Azacyclic compounds

3:Heteroaromatic compounds

4:Hydrocarbon derivatives

5:Hydroxypyrimidines

6:Ketimines

7:Organopnictogen compounds

8:Propargyl-type 1,3-dipolar organic compounds

9:Secondary alcohols

10:Secondary alkylarylamines

11:1,2-diol

12:Alcohol

13:Amine

14:Aromatic heteropolycyclic compound

15:Azacycle

16:Biopterin

17:Heteroaromatic compound

18:Hydrocarbon derivative

19:Hydroxypyrimidine

20:Imine

21:Ketimine

22:Organic 1,3-dipolar compound

23:Organic nitrogen compound

24:Organic oxygen compound

25:Organonitrogen compound

26:Organooxygen compound

27:Organopnictogen compound

28:Propargyl-type 1,3-dipolar organic compound

29:Pyrimidine

30:Secondary alcohol

31:Secondary aliphatic/aromatic amine

32:Secondary amine

33:7,8-dihydrobiopterin

本体论
term:Physiological effect

definition:The effect on an organism physiology, resulting from its exposure to a chemical.

parent_id:

level:1

type:parent

term:Health effect

definition:A health condition or observation associated with a stimuli or with a biological activity of a chemical.

parent_id:7693

*level:2

type:parent

term:Health condition

definition:A health effect that consists on short or long-term disease, condition, disorder, syndrome or constant abnormality.

parent_id:7694

**level:3

type:parent

term:Kidney disease

definition:A urinary system disease that is located in the kidney. (do).

parent_id:7695

***level:4

type:child

synonym:Renal disease

synonym:Nephropathy

term:Disposition

definition:A concept that describes the origin of a chemical, its location within an organism, or its route of exposure.

parent_id:

level:1

type:parent

term:Source

definition:Natural or synthetic origin of a chemical.

parent_id:7724

*level:2

type:parent

term:Endogenous

definition:

parent_id:7735

**level:3

type:child

term:Biological location

definition:The physiological origin within an organism, including anatomical compnents, biofluids and excreta.

parent_id:7724

*level:2

type:parent

term:Biofluid and excreta

definition:A liquid, semi-solid or solid material originating in the body.

parent_id:7725

**level:3

type:parent

term:Feces

definition:The material discharged from the bowel during defecation. It consists of undigested food, intestinal mucus, epithelial cells, and bacteria.

parent_id:7731

***level:4

type:child

synonym:Fecal

synonym:Stool

synonym:Faecal

synonym:Faeces

term:Saliva

definition:The watery fluid in the mouth made by the salivary glands. saliva moistens food to help digestion and it helps protect the mouth against infections. (nci).

parent_id:7731

***level:4

type:child

term:Blood

definition:A liquid tissue with the primary function of transporting oxygen and carbon dioxide (nci). it supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection.

parent_id:7731

***level:4

type:child

term:Cerebrospinal fluid

definition:The fluid that is contained within the brain ventricles, the subarachnoid space and the central canal of the spinal cord. (nci).

parent_id:7731

***level:4

type:child

synonym:Csf

term:Subcellular

definition:An anatomical organizational level including a component within a biological cell .

parent_id:7725

**level:3

type:parent

term:Cytoplasm

definition:The portion of the cell contained within the plasma membrane but excluding the nucleus.

parent_id:7730

***level:4

type:child

synonym:Cytoplasma

term:Mitochondria

definition:

parent_id:7730

***level:4

type:child

term:Process

definition:Biological or chemical events, or a series thereof, leading to a known function or end-product.

parent_id:

level:1

type:parent

term:Naturally occurring process

definition:Naturally-occurring molecular events or a series thereof, leading to a known function or end-product.

parent_id:7659

*level:2

type:parent

term:Biological process

definition:Biological or chemical events or a series thereof, leading to a known function or end-product within an organism.

parent_id:7660

**level:3

type:parent

term:Biochemical pathway

definition:A linked series of chemical reactions that occur in a defined order within or between organism cells, and lead to a known function or end product.

parent_id:7661

***level:4

type:parent

状态
Solid
实验性质
预测性质
1:

kind:logp

value:-1.43

source:ALOGPS

2:

kind:logs

value:-2.17

source:ALOGPS

3:

kind:solubility

value:1.63 g/L

source:ALOGPS

4:

kind:logp

value:-2.3

source:ChemAxon

5:

kind:pka_strongest_acidic

value:9.91

source:ChemAxon

6:

kind:pka_strongest_basic

value:0.4

source:ChemAxon

7:

kind:iupac

value:2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-1,4,7,8-tetrahydropteridin-4-one

source:ChemAxon

8:

kind:average_mass

value:239.2312

source:ChemAxon

9:

kind:mono_mass

value:239.101839307

source:ChemAxon

10:

kind:smiles

value:C[C@H](O)[C@H](O)C1=NC2=C(NC1)NC(N)=NC2=O

source:ChemAxon

11:

kind:formula

value:C9H13N5O3

source:ChemAxon

12:

kind:inchi

value:InChI=1S/C9H13N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3,6,15-16H,2H2,1H3,(H4,10,11,13,14,17)/t3-,6-/m0/s1

source:ChemAxon

13:

kind:inchikey

value:FEMXZDUTFRTWPE-DZSWIPIPSA-N

source:ChemAxon

14:

kind:polar_surface_area

value:132.33

source:ChemAxon

15:

kind:refractivity

value:68.11

source:ChemAxon

16:

kind:polarizability

value:23.11

source:ChemAxon

17:

kind:rotatable_bond_count

value:2

source:ChemAxon

18:

kind:acceptor_count

value:8

source:ChemAxon

19:

kind:donor_count

value:5

source:ChemAxon

20:

kind:physiological_charge

value:0

source:ChemAxon

21:

kind:formal_charge

value:0

source:ChemAxon

22:

kind:number_of_rings

value:2

source:ChemAxon

23:

kind:bioavailability

value:Yes

source:ChemAxon

24:

kind:rule_of_five

value:Yes

source:ChemAxon

25:

kind:ghose_filter

value:No

source:ChemAxon

26:

kind:veber_rule

value:No

source:ChemAxon

27:

kind:mddr_like_rule

value:No

source:ChemAxon

光谱
生物学性质
1:

cellular:(1):Cytoplasm

2:

biospecimen:(1):Blood

biospecimen:(2):Cerebrospinal Fluid (CSF)

biospecimen:(3):Feces

biospecimen:(4):Saliva

3:

4:

[1]:

name:Aromatic L-Aminoacid Decarboxylase Deficiency

smpdb_id:SMP00170

kegg_map_id:

[2]:

name:Dopa-responsive dystonia

smpdb_id:SMP00486

kegg_map_id:

[3]:

name:Hyperphenylalaniemia due to guanosine triphosphate cyclohydrolase deficiency

smpdb_id:SMP00487

kegg_map_id:

[4]:

name:Hyperphenylalaninemia due to 6-pyruvoyltetrahydropterin synthase deficiency (ptps)

smpdb_id:SMP00488

kegg_map_id:

[5]:

name:Hyperphenylalaninemia due to dhpr-deficiency

smpdb_id:SMP00489

kegg_map_id:

[6]:

name:Pterine Biosynthesis

smpdb_id:SMP00005

kegg_map_id:map00790

[7]:

name:Segawa syndrome

smpdb_id:SMP00490

kegg_map_id:

[8]:

name:Sepiapterin reductase deficiency

smpdb_id:SMP00491

kegg_map_id:

[9]:

name:Tyrosine hydroxylase deficiency

smpdb_id:SMP00497

kegg_map_id:

[10]:

name:Tyrosine metabolism

smpdb_id:

kegg_map_id:map00350

正常浓度
1:

biospecimen:Blood

concentration_value:0.006 +/- 0.0003

concentration_units:uM

subject_age:Adult (>18 years old)

subject_sex:Both

subject_condition:Normal

2:

biospecimen:Cerebrospinal Fluid (CSF)

concentration_value:0.0004-0.014

concentration_units:uM

subject_age:Adult (>18 years old)

subject_sex:Both

subject_condition:Normal

3:

biospecimen:Saliva

concentration_value:8.25 +/- 8.34

concentration_units:uM

subject_age:Adult (>18 years old)

subject_sex:Female

subject_condition:Normal

4:

biospecimen:Saliva

concentration_value:1.22 +/- 3.60

concentration_units:uM

subject_age:Adult (>18 years old)

subject_sex:Not Specified

subject_condition:Normal

5:

biospecimen:Saliva

concentration_value:10.8 +/- 14.7

concentration_units:uM

subject_age:Adult (>18 years old)

subject_sex:Not Specified

subject_condition:Normal

6:

biospecimen:Saliva

concentration_value:23.6 +/- 28.7

concentration_units:uM

subject_age:Adult (>18 years old)

subject_sex:Both

subject_condition:Normal

异常浓度
1:

biospecimen:Blood

concentration_value:0.0635 +/- 0.0041

concentration_units:uM

patient_age:Adult (>18 years old)

patient_sex:Both

patient_information:Kidney disease

2:

biospecimen:Feces

concentration_value:

concentration_units:

patient_age:Children (1-13 years old)

patient_sex:Both

patient_information:Enthesitis-related arthritis

3:

biospecimen:Feces

concentration_value:

concentration_units:

patient_age:Adult (>18 years old)

patient_sex:Both

patient_information:Colorectal Cancer

疾病参考
1:

name:Kidney disease

omim_id:

[1]:

reference_text:McGregor DO, Dellow WJ, Lever M, George PM, Robson RA, Chambers ST: Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. Kidney Int. 2001 Jun;59(6):2267-72.

pubmed_id:11380830

[2]:

reference_text:Ehrenpreis ED, Salvino M, Craig RM: Improving the serum D-xylose test for the identification of patients with small intestinal malabsorption. J Clin Gastroenterol. 2001 Jul;33(1):36-40.

pubmed_id:11418788

[3]:

reference_text:Jankowski J, van der Giet M, Jankowski V, Schmidt S, Hemeier M, Mahn B, Giebing G, Tolle M, Luftmann H, Schluter H, Zidek W, Tepel M: Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. J Clin Invest. 2003 Jul;112(2):256-64.

pubmed_id:12865413

[4]:

reference_text:Gill DS, Fonseca VA, Barradas MA, Balliod R, Moorhead JF, Dandona P: Plasma histamine in patients with chronic renal failure and nephrotic syndrome. J Clin Pathol. 1991 Mar;44(3):243-5.

pubmed_id:2013627

[5]:

reference_text:Niwa T, Takeda N, Yoshizumi H: RNA metabolism in uremic patients: accumulation of modified ribonucleosides in uremic serum. Technical note. Kidney Int. 1998 Jun;53(6):1801-6.

pubmed_id:9607216

[6]:

reference_text:Takagi T, Chung TG, Saito A: Determination of polyamines in hydrolysates of uremic plasma by high-performance cation-exchange column chromatography. J Chromatogr. 1983 Feb 11;272(2):279-85.

pubmed_id:6833425

[7]:

reference_text:Burke RA, Moberly JB, Patel H, Shockley TR, Martis L: Maltose and isomaltose in uremic plasma following icodextrin administration. Adv Perit Dial. 1998;14:120-3.

pubmed_id:10649708

[8]:

reference_text:Fleck C, Schweitzer F, Karge E, Busch M, Stein G: Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. Clin Chim Acta. 2003 Oct;336(1-2):1-12.

pubmed_id:14500028

[9]:

reference_text:Raj DS, Ouwendyk M, Francoeur R, Pierratos A: Plasma amino acid profile on nocturnal hemodialysis. Blood Purif. 2000;18(2):97-102.

pubmed_id:10838467

[10]:

reference_text:Liebich HM, Woll J: Volatile substances in blood serum: profile analysis and quantitative determination. J Chromatogr. 1977 Nov 11;142:505-16.

pubmed_id:914932

[11]:

reference_text:Galley HF, Le Cras AE, Yassen K, Grant IS, Webster NR: Circulating tetrahydrobiopterin concentrations in patients with septic shock. Br J Anaesth. 2001 Apr;86(4):578-80.

pubmed_id:11573638

[12]:

reference_text:Paniagua R, Claure R, Amato D, Flores E, Perez A, Exaire E: Effects of oral administration of zinc and diiodohydroxyquinolein on plasma zinc levels of uremic patients. Nephron. 1995;69(2):147-50.

pubmed_id:7723896

[13]:

reference_text:Chuang CK, Lin SP, Chen HH, Chen YC, Wang TJ, Shieh WH, Wu CJ: Plasma free amino acids and their metabolites in Taiwanese patients on hemodialysis and continuous ambulatory peritoneal dialysis. Clin Chim Acta. 2006 Feb;364(1-2):209-16. Epub 2005 Aug 8.

pubmed_id:16087168

[14]:

reference_text:Butscheid M, Schafer C, Brenner S, Alscher D, Murdter T, Niwa T, Frischmann M, Pischetsrieder M, Klotz U: Unchanged serum levels of advanced glycation endproducts in patients with liver disease. Naunyn Schmiedebergs Arch Pharmacol. 2007 Aug;375(6):401-6. Epub 2007 Jun 15.

pubmed_id:17571253

[15]:

reference_text:Stenvinkel P, Rodriguez-Ayala E, Massy ZA, Qureshi AR, Barany P, Fellstrom B, Heimburger O, Lindholm B, Alvestrand A: Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2006 Mar;1(2):281-7. Epub 2006 Feb 1.

pubmed_id:17699218

[16]:

reference_text:Bain MA, Faull R, Milne RW, Evans AM: Oral L-carnitine: metabolite formation and hemodialysis. Curr Drug Metab. 2006 Oct;7(7):811-6.

pubmed_id:17073580

[17]:

reference_text:Bain MA, Faull R, Fornasini G, Milne RW, Evans AM: Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. Nephrol Dial Transplant. 2006 May;21(5):1300-4. Epub 2006 Jan 9.

pubmed_id:16401621

[18]:

reference_text:Teerlink T, Hennekes MW, Mulder C, Brulez HF: Determination of dimethylamine in biological samples by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1997 Apr 11;691(2):269-76.

pubmed_id:9174262

[19]:

reference_text:Yokoyama K, Tajima M, Yoshida H, Nakayama M, Tokutome G, Sakagami H, Hosoya T: Plasma pteridine concentrations in patients with chronic renal failure. Nephrol Dial Transplant. 2002 Jun;17(6):1032-6.

pubmed_id:12032193

[20]:

reference_text:Paroni R, Ceriotti F, Galanello R, Battista Leoni G, Panico A, Scurati E, Paleari R, Chemello L, Quaino V, Scaldaferri L, Lapolla A, Mosca A: Performance characteristics and clinical utility of an enzymatic method for the measurement of glycated albumin in plasma. Clin Biochem. 2007 Dec;40(18):1398-405. Epub 2007 Aug 10.

pubmed_id:17919531

[21]:

reference_text:Nieren- und Hochdruckkrankheiten (1978), 7(2), 62-74 (translated from German Kidney and Hypertension).

pubmed_id:

2:

name:Colorectal cancer

omim_id:114500

[1]:

reference_text:Ishiwata S, Itoh K, Yamaguchi T, Ishida N, Mizugaki M: Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA. Tohoku J Exp Med. 1995 May;176(1):61-8.

pubmed_id:7482520

[2]:

reference_text:Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed. 2009 Apr;22(3):342-8. doi: 10.1002/nbm.1345.

pubmed_id:19006102

[3]:

reference_text:Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP: Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8):e70803. doi: 10.1371/journal.pone.0070803. Print 2013.

pubmed_id:23940645

[4]:

reference_text:Phua LC, Chue XP, Koh PK, Cheah PY, Ho HK, Chan EC: Non-invasive fecal metabonomic detection of colorectal cancer. Cancer Biol Ther. 2014 Apr;15(4):389-97. doi: 10.4161/cbt.27625. Epub 2014 Jan 14.

pubmed_id:24424155

[5]:

reference_text:Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB: Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med. 2010 Feb 15;8:13. doi: 10.1186/1741-7015-8-13.

pubmed_id:20156336

[6]:

reference_text:Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 2009 Oct;8(10):4844-50. doi: 10.1021/pr9004162.

pubmed_id:19678709

[7]:

reference_text:Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28.

pubmed_id:22148915

[8]:

reference_text:Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14.

pubmed_id:25105552

[9]:

reference_text:Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M: Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012 May;26(5):548-58. doi: 10.1002/bmc.1671. Epub 2011 Jul 20.

pubmed_id:21773981

[10]:

reference_text:Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18.

pubmed_id:25037050

[11]:

reference_text:Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016.

pubmed_id:27015276

[12]:

reference_text:Lin Y, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R: NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget. 2016 May 17;7(20):29454-64. doi: 10.18632/oncotarget.8762.

pubmed_id:27107423

[13]:

reference_text:Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016.

pubmed_id:27275383

[14]:

reference_text:Wang X, Wang J, Rao B, Deng L: Gut flora profiling and fecal metabolite composition of colorectal cancer patients and healthy individuals. Exp Ther Med. 2017 Jun;13(6):2848-2854. doi: 10.3892/etm.2017.4367. Epub 2017 Apr 20.

pubmed_id:28587349

[15]:

reference_text:Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Sandrine Paule Claus. Metabolomics of fecal samples: A practical consideration. Trends in Food Science & Technology. Vol. 57, Part B, Nov. 2016, p.244-255: http://www.sciencedirect.com/science/article/pii/S0924224416301984

KEGG数据库编号
C02953
DrugBank数据库编号
DB04400
foodb数据库编号
FDB021884
ChemSpider数据库编号
106382
公共化学化合物编号
119055
PDB数据库编号
生物利益的化学实体数据库编号
43029
knapsack数据库编号
维基百科编号
Dihydrobiopterin
代谢途径的数据库编号
CPD-15159
苯酚资源管理器化合物数据库编号
比格数据库编号
梅林编号
虚拟机身份证编号
CE2705
fbonto数据库编号
综合参考
Gal E M. Synthesis and quantitative aspects of dihydrobiopterin control of cerebral serotonin levels. Advances in experimental medicine and biology (1981), 133 197-206.
一般参考
1:

protein_accession:HMDBP00087

name:Tyrosinase

uniprot_id:P14679

gene_name:TYR

protein_type:Unknown

2:

protein_accession:HMDBP00273

name:Tyrosine 3-monooxygenase

uniprot_id:P07101

gene_name:TH

protein_type:Enzyme

3:

protein_accession:HMDBP00436

name:Sepiapterin reductase

uniprot_id:P35270

gene_name:SPR

protein_type:Enzyme

4:

protein_accession:HMDBP00469

name:Tryptophan 5-hydroxylase 1

uniprot_id:P17752

gene_name:TPH1

protein_type:Enzyme

5:

protein_accession:HMDBP00545

name:Dihydropteridine reductase

uniprot_id:P09417

gene_name:QDPR

protein_type:Unknown

6:

protein_accession:HMDBP00790

name:Dihydrofolate reductase

uniprot_id:P00374

gene_name:DHFR

protein_type:Enzyme

7:

protein_accession:HMDBP00928

name:Nitric oxide synthase, brain

uniprot_id:P29475

gene_name:NOS1

protein_type:Unknown

8:

protein_accession:HMDBP00929

name:Nitric oxide synthase, endothelial

uniprot_id:P29474

gene_name:NOS3

protein_type:Unknown

9:

protein_accession:HMDBP02872

name:Pterin-4-alpha-carbinolamine dehydratase

uniprot_id:P61457

gene_name:PCBD1

protein_type:Enzyme

10:

protein_accession:HMDBP10140

name:Pterin-4-alpha-carbinolamine dehydratase 2

uniprot_id:Q9H0N5

gene_name:PCBD2

protein_type:Enzyme

11:

protein_accession:HMDBP11613

name:Alkylglycerol monooxygenase

uniprot_id:Q6ZNB7

gene_name:AGMO

protein_type:Unknown

蛋白质结合
1:

reference_text:Bonafe L, Thony B, Penzien JM, Czarnecki B, Blau N: Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopterin-dependent monoamine-neurotransmitter deficiency without hyperphenylalaninemia. Am J Hum Genet. 2001 Aug;69(2):269-77. Epub 2001 Jul 6.

pubmed_id:11443547

2:

reference_text:Goodwill KE, Sabatier C, Stevens RC: Crystal structure of tyrosine hydroxylase with bound cofactor analogue and iron at 2.3 A resolution: self-hydroxylation of Phe300 and the pterin-binding site. Biochemistry. 1998 Sep 29;37(39):13437-45.

pubmed_id:9753429

3:

reference_text:Leeming RJ, Blair JA, Melikian V, O'Gorman DJ: Biopterin derivatives in human body fluids and tissues. J Clin Pathol. 1976 May;29(5):444-51.

pubmed_id:932231

4:

reference_text:Witteveen CF, Giovanelli J, Kaufman S: Reduction of quinonoid dihydrobiopterin to tetrahydrobiopterin by nitric oxide synthase. J Biol Chem. 1996 Feb 23;271(8):4143-7.

pubmed_id:8626754

5:

reference_text:Niederwieser A, Curtius HC, Bettoni O, Bieri J, Schircks B, Viscontini M, Schaub J: Atypical phenylketonuria caused by 7, 8-dihydrobiopterin synthetase deficiency. Lancet. 1979 Jan 20;1(8108):131-3.

pubmed_id:84153

6:

reference_text:Topal G, Brunet A, Millanvoye E, Boucher JL, Rendu F, Devynck MA, David-Dufilho M: Homocysteine induces oxidative stress by uncoupling of NO synthase activity through reduction of tetrahydrobiopterin. Free Radic Biol Med. 2004 Jun 15;36(12):1532-41.

pubmed_id:15182855

7:

reference_text:Yokoyama K, Tajima M, Yoshida H, Nakayama M, Tokutome G, Sakagami H, Hosoya T: Plasma pteridine concentrations in patients with chronic renal failure. Nephrol Dial Transplant. 2002 Jun;17(6):1032-6.

pubmed_id:12032193

8:

reference_text:Hagedoorn PL, Schmidt PP, Andersson KK, Hagen WR, Flatmark T, Martinez A: The effect of substrate, dihydrobiopterin, and dopamine on the EPR spectroscopic properties and the midpoint potential of the catalytic iron in recombinant human phenylalanine hydroxylase. J Biol Chem. 2001 Jun 22;276(25):22850-6. Epub 2001 Apr 11.

pubmed_id:11301319

9:

reference_text:Howells DW, Hyland K: Direct analysis of tetrahydrobiopterin in cerebrospinal fluid by high-performance liquid chromatography with redox electrochemistry: prevention of autoxidation during storage and analysis. Clin Chim Acta. 1987 Jul 30;167(1):23-30.

pubmed_id:3665086

10:

reference_text:Shinozaki K, Hirayama A, Nishio Y, Yoshida Y, Ohtani T, Okamura T, Masada M, Kikkawa R, Kodama K, Kashiwagi A: Coronary endothelial dysfunction in the insulin-resistant state is linked to abnormal pteridine metabolism and vascular oxidative stress. J Am Coll Cardiol. 2001 Dec;38(7):1821-8.

pubmed_id:11738280

11:

reference_text:Yang S, Jan YH, Mishin V, Richardson JR, Hossain MM, Heindel ND, Heck DE, Laskin DL, Laskin JD: Sulfa drugs inhibit sepiapterin reduction and chemical redox cycling by sepiapterin reductase. J Pharmacol Exp Ther. 2015 Mar;352(3):529-40. doi: 10.1124/jpet.114.221572. Epub 2014 Dec 30.

pubmed_id:25550200

免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:国家药品监督管理局| 国家中医药管理局| SDA药品评审中心| 医加医疗器械| 膏药生产厂家| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:33068302000535
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3